Weikang Bio-Technology Announces Update on Newest Products

HARBIN, China, Jan. 11, 2011 /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced an update regarding sales of its Rongrun Good Health Package, a bundled product launched in the third quarter of 2010. The Good Health Package includes four SFDA-approved products produced by Heilongjiang Weikang: Perilla Seed Soft Capsule, Yangshen Dan, Forest Frog Oil, and Kidney Boost Tonic.

Perilla Seed Soft Capsule, a functional food supplement containing pure natural perilla seed oil, contributed approximately $2.31 million to the Company's revenue from its launch through the end of 2010. The Company's Kidney Boost Tonic, which has new packaging and is intended to improve kidney function and boost the immune system, contributed approximately $2.73 million to total revenues over the same period. Yangshen Dan, which is designed to reduce the symptoms of prostatic hypertrophy and improve blood flow to the small capillaries and arteries, contributed roughly $2.12 million in revenue through the end of 2010. Forest Frog Oil, which is formulated to improve overall immune function and serve as a preventative therapeutic for a variety of ailments, contributed approximately $2.01 million in revenue from its launch through the end of 2010.

"We are pleased by the positive response our Rongrun Good Health Package has received thus far in the market," commented Dr. Yin Wang, Chairman and CEO of Weikang Bio-Technology Group. "Since we announced the launch of this bundled product at the end of the third quarter, it has contributed a total of $9.17 million to our fiscal 2010 revenues. We continue to market our proprietary products aggressively to gain brand recognition and market share, and we expect the Good Health Package and other new products to contribute significantly to our business in 2011."

About Weikang Bio-Technology Group Co., Inc.

Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang Pharmaceutical Co., Ltd.

For more information, please visit http://www.weikangbio.com.

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.  These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.